J
Johanne Martel-Pelletier
Researcher at Université de Montréal
Publications - 430
Citations - 28040
Johanne Martel-Pelletier is an academic researcher from Université de Montréal. The author has contributed to research in topics: Osteoarthritis & Cartilage. The author has an hindex of 82, co-authored 414 publications receiving 25451 citations.
Papers
More filters
Journal ArticleDOI
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
TL;DR: The current knowledge regarding the role of proinflammatory cytokines in the pathophysiology of OA is discussed and the potential of anticytokine therapy in the treatment of this disease is addressed.
Journal ArticleDOI
Osteoarthritis, an inflammatory disease: Potential implication for the selection of new therapeutic targets
TL;DR: There is now strong evidence that the structural changes globally observed in OA are due to a combination of factors, ranging from the mechanical to the biochemical, including endogenous factors such as type II collagen mutation or dysplastic conditions.
Journal Article
The role of cytokines in osteoarthritis pathophysiology.
TL;DR: The neutralization of IL-1 and/or TNF-alpha up-regulation of MMP gene expression appears to be a logical development in the potential medical therapy of OA, and experimental evidence showing that neutralizing T NF-alpha suppressed cartilage degradation in arthritis also support such strategy.
Journal ArticleDOI
The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis.
Pascal Reboul,Jean-Pierre Pelletier,Ginette Tardif,Jean-Marie Cloutier,Johanne Martel-Pelletier +4 more
TL;DR: It is shown that human chondrocytes had the ability to produce collagenase-3 as a proenzyme and as a glycosylated doublet, and its involvement in human OA cartilage patho-physiology is suggested.
Journal ArticleDOI
Cartilage in normal and osteoarthritis conditions.
TL;DR: Osteoarthritis is characterized by degradation and loss of articular cartilage, subchondral bone remodeling, and, at the clinical stage of the disease, inflammation of the synovial membrane.